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ABSTRACT
 
Objectives:
 
Cost–utility analysis in renal transplant pop-
ulations requires the use of a generic instrument for health
status measurement that generates a single value for
health. Such instruments should be widely applicable in
diverse patient populations and their validity should be
established. The aim of this study was to explore the
validity of the EQ-5D in renal transplant patients.
Methods: The EQ-5D was compared with the Short-
Form 36 Health Survey (SF-36), the modiﬁed transplant
symptom occurrence and symptom distress (MTSOSD)
scale, the short-form Beck Depression Inventory (BDI),
and the State Trait Anxiety Inventory (STAI). Construct
and concurrent validity were tested on cross-sectional
data of 350 patients.
Results: Construct validity is good for some but not all
EQ-5D dimensions, and the EQ-5D discriminates well
among groups of patients with different health states
according to the SF-36, MTSOSD scale, BDI, and STAI
and between patients and the general public. Concurrent
validity is good, as shown by the correspondence of EQ-
5D and SF-36 results.
Conclusion: It is concluded that the EQ-5D is a valid
instrument for the measurement of health status in renal
transplant patients.
Keywords: concurrent validity, construct validity, EQ-
5D, renal transplantation.
 
Introduction
 
The increasing need to set priorities in health care
has urged health professionals to develop instru-
ments that reﬂect patients’ subjective health status
and use these in economic evaluations. Subjective
health status is the personal perception of a patient’s
own health. This concept is closely related to the
concept health-related quality of life—and in the lit-
erature both concepts are used interchangeably—
although health-related quality of life can be inter-
preted more broadly, including all aspects of life
that have a possible relationship with health.
Because there is a large variability in the aspects of
life that are considered important for an individual’s
health-related quality of life, health-related quality
of life is more difﬁcult to measure and it cannot be
claimed that a generic instrument, with a limited
number of non-disease-speciﬁc dimensions, meas-
ures actual health-related quality of life.
One of the concerns in using generic question-
naires, as required for economic evaluations, is that
they may fail to capture small but relevant changes
in the health status of speciﬁc patient groups. Devel-
opers of health status measurement instruments
necessarily make trade-offs between simplicity and
comprehensiveness. Simplicity of the instrument is
crucial for the feasibility of using the instrument in
routine practice or in large clinical or economic
studies. Moreover, the instrument should allow the
translation of the health state description into one
single index value to allow the calculation of the
number of quality-adjusted life-years gained by an
intervention compared to other interventions.
The EQ-5D is a generic ﬁve-dimensional instru-
ment that is used worldwide for health status meas-
urement [1,2]. Each health state description
corresponds with an index value, derived from the
general public [3]. The validity and reliability of the
EQ-5D have been tested in the general public of dif-
ferent countries [4–7] as well as in several patient
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populations, such as rheumatoid arthritis patients
[8] and patients with osteoarthritis of the knee [9],
lower limb ischemia [10], sleep apnea [11], chronic
obstructive pulmonary disease [12], and intestinal
failure [13].
To be useful for comparisons across patient
groups, the EQ-5D should be valid in all patient
populations. The validity of an instrument is “the
degree to which evidence and theory support the
interpretation of the test scores entailed by the pro-
posed uses of tests” [14]
 
.
 
 The proposed use of the
EQ-5D is as an outcome measure in economic eval-
uations. Hence, to be valid the EQ-5D must allow
sensible comparisons among patient groups and/or
patients with different characteristics. The problem
with evaluating the validity of an instrument that
measures subjective health status, such as the EQ-
5D, is that there is no gold standard against which
the instrument can be tested. A number of concepts
that focus on different aspects of validity have been
described in the literature. A recent classiﬁcation of
validity concepts explains which evidence is needed
to perform a validity test: evidence on test content,
response process, internal structure, relations to
other variables, and consequences of testing (see
Goodwin [15] for a full discussion).
As yet, there is no evidence on the validity of the
EQ-5D in the renal transplant population. Such evi-
dence is important, however, to allow decision mak-
ers to assess the usefulness of the EQ-5D for
economic evaluations that are used to set priorities
between different disease areas. Evidence on the
validity of the EQ-5D in other disease areas does
not guarantee validity in the renal transplant pop-
ulation. The aim of this study was therefore to
assess the construct and concurrent validity of the
EQ-5D in renal transplant patients.
 
Methods
 
Patient Sample
 
The analyses in this article are based on the data of
a cross-sectional descriptive study that aimed to
examine the subjective health status of patients fol-
lowing a tacrolimus-based immunosuppressive reg-
imen after renal transplantation (RTX) [16]. The
sample consisted of 361 renal transplant patients
from 3 RTX centers in Belgium and the Nether-
lands. Patients were considered eligible for partici-
pation in the study if they were 18 years of age or
older, literate, and Dutch or French speaking; had a
post-transplant status of at least 6 months; and had
not received a combined transplantation (e.g., kid-
ney-pancreas) or a second renal transplantation. All
patients were asked for a written informed consent
before the questionnaires were distributed. Eleven
patients refused to participate in the study, resulting
in a complete data set for 350 patients. At the
moment of inclusion, patients had a median post-
RTX status of 16.7 months (
 
Q
 
1
 
 
 
=
 
 7.9; 
 
Q
 
3
 
 
 
=
 
 38.6).
 
Variables and Measurement
 
The validity of the EQ-5D was tested by means of
comparisons with already validated instruments for
the measurement of different aspects of health sta-
tus in the renal transplant population. Instruments
include the Short-Form 36 Health Survey (SF-36)
[17] as a generic proﬁle measure for health status,
the short-form Beck Depression Inventory (BDI)
[18] for the measurement of depressive symptoma-
tology, and the modiﬁed transplant symptom occur-
rence and symptom distress (MTSOSD) scale [19]
for the measurement of symptom experience and
symptom distress associated with side effects of
immunosuppressive drugs. All 350 patients who
agreed to participate in the study were given an SF-
36, an EQ-5D, an MTSOSD scale, and a BDI at
inclusion in the study.
 
EQ-5D.
 
The EQ-5D is a simple two-page question-
naire consisting of a self-classiﬁer and a visual ana-
log scale (VAS) on which patients can value their
current health state. The developers of the EQ-5D
relied on existing instruments for the measurement
of health status, such as the quality of well-being
scale, the Nottingham Health Proﬁle, the Sickness
Impact Proﬁle, and the Rosser Index [20].
The self-classiﬁer includes ﬁve dimensions
(mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression) with three levels of
severity in each dimension (no problems, some
problems, and severe problems). This classiﬁcation
allows for the description of 243 (3
 
5
 
) different
health states. Each of these 243 health states corre-
sponds with a single index measure between 0
(
 
=
 
 dead) and 1 (
 
=
 
 perfect health), derived from and
reﬂecting the preferences of the general public [3].
The index values used for the analyses in this study
were derived from a large Flemish EuroQol valida-
tion survey [21].
The reliability of the EQ-5D with VAS is accept-
able, as shown by studies in different patient pop-
ulations and the general public [8,9,12,22–26]. The
reported intraclass correlation coefﬁcients range
from 0.7 to 0.93.
 
Short-form 36 health survey.
 
The SF-36 is a gen-
eric instrument for the measurement of patients’
current health status. The SF-36 is often referred as
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an instrument that measures quality of life. Given
the far more limited nature of health status com-
pared to quality of life, however, preference is given
to the term health status. The SF-36 contains 36
items that cover eight dimensions of health: physical
functioning, role limitation due to physical prob-
lems, bodily pain, general health perception, vital-
ity, social functioning, role limitation due to
emotional problems, and mental health [17]. It
results in a proﬁle for health, with a value between
0 (worst health) and 100 (best health) for each
dimension. Because the SF-36 does not yield one
single index score for general health status, it has, so
far, been inappropriate for economic evaluations.
Recent attempts have been made, however, to derive
a preference-based single index value from a revised
six-dimensional classiﬁcation of the SF-36 [27].
This approach is still under development.
The validity of the subscales of the SF-36 has
been established against clinically deﬁned groups in
general [28] and renal transplant populations in
particular [29,30]. The SF-36 has been used fre-
quently in studies on RTX for the measurement of
health status [29–38] as well as for the validation of
a new disease-speciﬁc instrument [39]. Piehlmeier
and colleagues [40] examined the validity, reliabil-
ity, and responsiveness of the SF-36 in a renal trans-
plant population and concluded that the SF-36 is a
reliable (internal consistency), valid (high correla-
tion with overall evaluations of the health-related
quality of life), discriminant (detects differences in
clinical status), and responsive (detects differences
in patients before and after transplantation) instru-
ment for evaluating subjective health status.
Short-form Beck Depression Inventory. The short-
form BDI is an instrument containing 13 items that
measures depressive symptomatology in patients
[18,41]. In contrast to the original version of the
BDI with 22 items [42], the short-form BDI does
not include any physical symptoms of depression,
thus preventing false-positive results in chronically
ill patients such as renal transplant recipients. The
13 items are scored with three response categories
[1–3]. The total score is obtained by summing the
scores on the individual items. On the basis of their
individual total score on the BDI, patients are clas-
siﬁed into four categories: no depression (0–4), mild
depression (5–7), moderate depression (8–15), or
severe depression (16–39).
The BDI has been used frequently for the meas-
urement of depression in renal transplant popula-
tions [43–46]. One study examined the validity of
using the 22-item BDI in a renal transplant popula-
tion [47]. It was found that the symptoms that most
discriminate between depressed and nondepressed
renal transplant patients were the symptoms
included in the short-form BDI (e.g., death wish,
suicidal intention, guilt, dysphoric mood, and prob-
lems in concentration) [47]. Both the long- and the
short-form BDI have good internal consistency reli-
ability [48,49].
Modiﬁed transplant symptom occurrence and
symptom distress scale. The MTSOSD scale is a
45-item questionnaire about a patient’s perceived
occurrence of symptoms related to the side effects of
the immunosuppressive regimen after transplanta-
tion and the distress associated with these symp-
toms [19]. It includes symptoms such as increased
hair growth, itching, impotence, fatigue, and trem-
bling hands. The MTSOSD scale is a disease-speciﬁc
instrument, developed especially for the transplant
population. For each potential symptom, occur-
rence (cognitive component of symptom experi-
ence) is rated on a scale from 0 (never) to 4
(always), and distress (emotional component of
symptom experience) is rated on a scale from 0 (not
distressing) to 4 (extremely distressing). The psy-
chometric properties of the MTSOSD scale are
described elsewhere [19]. The authors conclude that
the MTSOSD scale is a valid instrument for the
measurement of symptom occurrence and symptom
distress related to side effects of immunosuppressive
therapy. Test–retest reliability was not assessed and
internal consistency could not be tested because the
conditions for this test were not satisﬁed.
 
Hypotheses
 
Based on prior research in the renal transplant pop-
ulation, ﬁve hypotheses were developed for this
study that address anticipated relationships
between the EQ-5D and other relevant variables.
The tested hypotheses and the instruments used are
schematically presented in Table 1.
Given that the SF-36 and the EQ-5D both claim
to measure (subjective) health status, the results
obtained with both instruments should be compa-
rable (H
 
4
 
). Results of the BDI and MTSOSD scale
should be comparable with the responses on the
EQ-5D dimensions anxiety/depression and pain/
discomfort, respectively, because both claim to
measure the same aspect of health (H
 
5
 
). Therefore,
patients were grouped by their response on the rel-
evant dimension of the EQ-5D, and scores on the
BDI, MTSOSD scale, and SF-36 were compared
among the patient groups. In case of comparisons
with the SF-36, it is expected that there are larger
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differences between the mean SF-36 scores of
patients grouped according to their response on
comparable domains of the EQ-5D (e.g., mobil-
ity
 
EQ-5D
 
 and physical functioning
 
SF-36
 
 or pain/
discomfort
 
EQ-5D
 
 and bodily pain
 
SF-36
 
) than between
the mean SF-36 scores of patients grouped accord-
ing to their response on noncomparable domains
of the EQ-5D (e.g., mobility
 
EQ-5D
 
 and role limita-
tions due to emotional problems
 
SF-36
 
). This should
reveal whether the EQ-5D dimension response dis-
tinguishes between groups of patients with higher
or lower mean SF-36 scores. For the BDI, it is
expected that the classiﬁcation of the EQ-5D into
“no depression,” “some depression,” and “severe
depression” reﬂects the classiﬁcation into no, mild,
moderate, and severe depressive symptomatology
of the BDI [41]. For the MTSOSD scale, it is
expected that mean total scores differ signiﬁcantly
between groups of patients with different levels of
pain/discomfort on the EQ-5D.
 
Statistical Analysis
 
Differences in percentages of patients reporting
problems on the respective dimensions of the EQ-
5D between men and women and among the differ-
ent age groups were tested by means of a chi-square
test statistic. Differences in EQ-5D index scores
among age groups were tested by means of a
Kruskal–Wallis test. For differences in EQ-5D index
scores between men and women an independent
sample Student’s 
 
t
 
 test could be used because of the
large number of patients in both groups. Age groups
were deﬁned as 10-year intervals between the ages
of 20 and 80.
Differences between percentage of patients
reporting problems on the ﬁve EQ-5D dimensions
and the percentage of respondents from the general
public were tested by means of a Fisher exact test,
because no single patient reported extreme prob-
lems with mobility.
Comparisons of BDI and MTSOSD scale scores
across patient groups were made by means of an
analysis of variance (ANOVA). For comparisons of
SF-36 scores across patient groups an independent
sample Student’s 
 
t
 
 test was used; response categories
were dichotomized because a very small proportion
of the respondents reported severe problems on the
EQ-5D dimensions. The nonparametric Spearman
rank correlation coefﬁcients were calculated
between EQ-5D index scores and SF-36 domain
scores because the EQ-5D index scores were not
normally distributed.
Symptom occurrence and symptom distress were
analyzed using ridit analysis [51,52]. Ridit analysis,
as used in this study, calculates the probability that
a respondent reports a level of symptom occurrence,
or distress, that is higher than the symptom occur-
rence, or distress, reported by a randomly selected
patient from the entire patient sample, given his or
her proﬁle of responses on all the symptoms. Ridits
are hence probabilities that are calculated for each
individual across all symptoms, both for symptom
occurrence and for symptom distress. Individual
ridit scores were compared with the ridits of all
patients in the sample; i.e., the entire patient sample
was used as the reference group with which individ-
ual scores were compared. For example, if a patient
has higher symptom occurrence than the “average”
patient from the entire sample, his or her ridit score
will be higher than 0.5. The “average” patient has a
ridit of 0.5: the probability that his or her level of
symptom occurrence is higher than a randomly
selected patient from the entire patient sample is
50%; the probability that it is lower is also 50%.
Ridits give an indication of the proﬁle of a patient.
A patient who reports high levels of symptom
 
Table 1
 
Hypotheses tested and instruments used in the validation study
 
Instruments
 
Construct validity
 
Convergent validity
 
H
 
1
 
An inverse relationship exists between age and level of  reported problems on mobility, self-care, usual 
activities, and pain/discomfort on the EQ-5D [2]
EQ-5D, demographic questionnaire
H
 
2
 
Women report more often anxiety/depression on the EQ-5D than men [50] EQ-5D, demographic questionnaire
 
Discriminant validity
 
H
 
3
 
The EQ-5D is able to discriminate between renal transplant patients and—presumably more 
healthy—people from the general Flemish public
EQ-5D
 
Concurrent validity
 
H
 
4
 
Differences in mean SF-36 scores between patients, grouped according to their response on the 
EQ-5D, are largest for comparable dimensions of  the SF-36 and the EQ-5D
EQ-5D, SF-36
H
 
5
 
The classiﬁcation of  patients according to their response on the anxiety/depression dimension and the 
pain/discomfort dimension of  the EQ-5D reﬂects the patterns obtained from the BDI and the 
MTSOSD scale, respectively
EQ-5D, BDI, MTSOSD scale
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occurrence or symptom distress will have a high
ridit score. The reason for using ridits is that they
summarize the ordinal answers on a large number
of questions into a single parameter for every
patient. Instead of analyzing the data on the level of
the separate symptoms, a more generalized analysis
is possible through ridits. Moreover, ridits allow
parametric statistical analyses on proﬁles of ordinal
data.
All statistical analyses were performed with SPSS
statistical software version 9.0 (SPSS Inc., Chicago,
IL, 1999). The level of signiﬁcance was set at 5%.
 
Results
 
Demographic Characteristics
 
Of the 350 patients included in the study, 59.7%
were men. The mean age of the men and women in
the sample was 51.7 years (SD 13.1 and 12.9 years,
respectively) and hence the mean age of all patients
was also 51.7 years (SD 13 years). Thirty-seven per-
cent of the respondents attained a primary school
level, 42.7% a secondary school level, and 18.6% a
higher educational degree. The remainder did not
have any educational degree.
 
Construct Validity
 
Convergent validity (H
 
1
 
 and H
 
2
 
).
 
The results with
respect to convergent validity show that older
patients have signiﬁcantly more problems on mobil-
ity than younger patients and have signiﬁcantly
lower EQ-5D index scores. No signiﬁcant differ-
ences are found for the other dimensions (Table 2).
Signiﬁcantly more women are anxious or
depressed than men. Men and women do not show
signiﬁcant differences on any other dimension of the
EQ-5D (Table 2).
 
Discriminant validity (H
 
3
 
).
 
A signiﬁcant difference
between the frequency of reported problems by
patients and the general public is found for all the
dimensions of the EQ-5D except for self-care
(Table 3). The difference in EQ-5D index scores is
also highly signiﬁcant.
Demographic characteristics of the patient group
are signiﬁcantly different from those of the general
public; patients are signiﬁcantly older (
 
P
 
 
 
=
 
 0.024)
and have higher educational levels (P = 0.001), and
there are more men in the patient sample than in the
general public sample (
 
P
 
 
 
<
 
 0.0005). A multivariate
analysis, in which the EQ-5D index values are cor-
rected for age, educational level, and sex, reveals
stable results, with patients having a lower EQ-5D
index score than people from the general public.
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Concurrent Validity (H
 
4
 
 and H
 
5
 
)
 
For the concurrent validity testing, patients were
grouped according to their responses on the EQ-5D
to see whether this classiﬁcation reﬂected the pat-
terns obtained with the SF-36, BDI, STAI, and
MTSOSD scale. Results for the SF-36 are presented
in Table 4.
Patients reporting some or severe problems on
the EQ-5D dimensions have signiﬁcantly lower SF-
36 scores for almost all SF-36 domains. A few
exceptions are observed. The difference in SF-36
scores for mental health among patients reporting
no, moderate, or severe problems on mobility is not
signiﬁcant (
 
P
 
 
 
=
 
 0.162). The same applies for the dif-
ference in scores on role limitation due to emotional
problems and mental health between groups report-
ing no, moderate, or extreme problems on self-care
(
 
P
 
 
 
=
 
 0.160 and 
 
P
 
 
 
=
 
 0.062). Differences are largest
between dimensions of the SF-36 and the EQ-5D
covering comparable domains of health (e.g.,
mobility
 
EQ-5D
 
 and physical functioning
 
SF-36
 
, mental
health
 
SF-36
 
 and anxiety/depression
 
EQ-5D
 
, bodily
pain
 
SF-36
 
 and pain/discomfort
 
EQ-5D
 
, physical role lim-
itation
 
SF-36
 
 and usual activities
 
EQ-5D
 
).
The range of possible scores on the different
health domains is larger in the SF-36 than in the
EQ-5D. In the EQ-5D the range of responses on the
level of the dimensions is, by design, limited to
three, whereas the domain scores in the SF-36 can
be any discrete number between 0 and 100. This
implies that the SF-36 has a higher potential to cap-
ture small changes in health status if these changes
manifest themselves in one health domain than the
EQ-5D.
Spearman rank correlation coefﬁcients between
the EQ-5D index scores and the SF-36 domain
range from 0.41 (with role limitation due to emo-
tional problems) to 0.68 (with bodily pain) (all
 
P
 
 
 
<
 
 0.01). The correlations with all other domains
of the SF-36 are also signiﬁcant on the 1% signiﬁ-
cance level. This means that more problems on any
domain of the SF-36 are associated with lower EQ-
5D index scores and vice versa.
For the BDI, it is found that the classiﬁcation into
“not,” “moderately,” or “severely” depressed
resulting from the responses on the anxiety/depres-
 
Table 3
 
Percentage of  respondents reporting no, some, and
severe problems on each of  the EQ-5D dimensions
 
Study sample
(n = 350)
General public
(n 
 
=
 
 967)
 
P
 
 value
Mobility
No problems 62.0 83.1
 
<
 
0.01*
Some problems 38.0 16.7
Severe problems 0 0.2
Self-care
No problems 92.9 95.0 0.17*
Some problems 6.6 4.1
Severe problems 0.6 0.9
Usual activities
No problems 68.9 82.5
 
<
 
0.01*
Some problems 27.1 15.9
Severe problems 4.0 1.6
Pain/discomfort
No problems 45.1 53.0 0.04*
Some problems 52.0 44.5
Severe problems 2.9 2.6
Anxiety/depression
No problems 69.4 77.3 0.01*
Some problems 26.9 21.7
Severe problems 3.7 1.0
EQ-5D index, mean
(SD)
0.73 (0.21) 0.81 (0.21)
 
<
 
0.01
 
†
 
*Fisher exact test.
 
†
 
Mann–Whitney 
 
U
 
 test.
Table 4 SF-36 scores by EQ-5D response
EQ-5D
SF-36 domain
GHPN PF SF RP RE BP MH V
Mobility
No problems 217 84.0 83.2 71.5 78.5 80.1 72.8 68.7 65.3
Any problems 133 55.3* 71.6* 45.9* 66.2* 63.3* 69.8 54.6* 53.7*
Self-care
No problems 325 75.8 80.3 64.3 74.9 75.3 72.3 64.7 61.9
Any problems 23 38.0* 58.5* 29.0* 60.0 53.4* 63.7 45.2* 47.9*
Usual activities
No problems 241 81.9 85.0 74.8 81.3 80.6 75.3 69.1 65.7
Any problems 95 53.6* 65.1* 33.0* 57.2* 58.4* 63.6* 50.5* 50.1*
Pain/discomfort
No problems 158 79.6 87.1 76.6 86.7 90.4 78.2 72.3 68.2
Any problems 182 67.7* 71.9* 49.6* 63.2* 60.0* 66.3* 56.0* 54.9*
Anxiety/depression
No problems 243 74.6 84.5 67.4 85.3 77.9 79.7 69.1 64.6
Any problems 94 69.6* 65.9* 49.0* 47.7* 64.3* 53.4* 50.3* 52.4*
*P < .01 according to an independent sample t test.
Abbreviations: PF, physical functioning; SF, social functioning; RP, role limitations due to physical problems; RE, role limitations due to emotional problems; BP, bodily
pain; MH, mental health; V, vitality; GHP, general health perception.
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sion dimension on the EQ-5D reﬂects the classiﬁca-
tion of the BDI into “no,” “mild,” “moderate,” and
“severe” depression [41] (Table 5). The majority of
the patients without depression according to the
BDI report no anxiety or depression on the EQ-5D
(80.6%). The balance is changed the more depres-
sive symptoms patients have according to the BDI.
Still a majority of patients with mild depression
report no anxiety or depression on the EQ-5D
(58.5%), but patients with moderate depression are
more likely to report some anxiety or depression on
the EQ-5D. Seventy-ﬁve percent of the patients with
severe depression according to the BDI also report
extreme anxiety or depression on the EQ-5D
(Table 5).
The concurrent validity of the EQ-5D with
respect to depression is also illustrated by the sig-
niﬁcant difference between the mean BDI scores
of the different groups of patients, deﬁned by
their response on the anxiety/depression dimen-
sion of the EQ-5D (Table 5). Patients with
extreme anxiety/depression according to the EQ-
5D have signiﬁcantly higher BDI scores than
patients with moderate or no anxiety/depression
according to the EQ-5D (P < 0.0005). The same
applies for patients with moderate anxiety/depres-
sion in comparison with patients with no anxiety/
depression.
Mean ridits for symptom occurrence and symp-
tom distress are signiﬁcantly different among
patients grouped by their level of pain/discomfort
(P < 0.01). Respondents reporting more pain/dis-
comfort have signiﬁcantly higher ridits (Fig. 1). This
means that the probability that a respondent reports
higher symptom experience and distress than a ran-
domly selected patient from the entire sample
increases as the level of problems reported on the
EQ-5D pain/discomfort dimension increases.
The negative correlations between the EQ-5Q
index  scores  and  the  MTSOSD  scale  scores
(r =  -0.386  for  symptom  experience  and  r=
-0.498 for symptom distress) are highly signiﬁcant
(P < 0.0005), meaning that the more symptoms
patients experience and the more distressed they
are about these symptoms, the lower their score for
overall health.
Table 5 Percentage of  patients reporting no, some, or extreme anxiety/depression, given their BDI classiﬁcation and mean BDI
score for respondents with different answers on the EQ-5D anxiety/depression dimension
EQ-5D: anxiety/depression
Classiﬁcation according to the short-form BDI
Total
BDI score
mean (SD)
No
depression
Mild
depression
Moderate
depression
Severe
depression
No problems 80.6 58.5 20.0 0 69.4 2.31 (2.59)
Some problems 18.2 39.6 65.0 25 26.9 5.59 (3.97)
Severe problems 1.2 1.9 15.0 75 3.7 12.54 (8.54)
Total 72.3 15.1 11.4 1.1 100 3.57 (4.06)
Figure 1 Box plots of  ridit scores for the symptom occurrence and symptom distress subscales of  the MTSOSD scale, according to response on
EQ-5D pain/discomfort.
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Discussion
The purpose of this study was to investigate the
construct and concurrent validity of the EQ-5D in
renal transplant recipients. The construct validity of
the instrument was tested by looking at the conver-
gent and discriminant validity of the instrument.
The hypothesis of an inverse relationship
between age and level of problems on mobility, self-
care, usual activities, and pain/discomfort (H1)
could not entirely be accepted. The expected rela-
tionship was seen only between age and mobility.
An unexpected pattern in frequency of reported
problems with self-care was observed. The percent-
age of patients reporting problems on the EQ-5D
self-care dimension was high in the category 30 to
39 years of age, declines up to 50 to 59 years of age,
and then increases again up to 70 to 79 years of age.
Unexpected patterns were also observed in the usual
activities and pain/discomfort dimensions. The
results are in contrast to most existing research in
general populations [2,53–56], in which an almost
systematic increase in frequency of reported prob-
lems is observed on all dimensions, except for anx-
iety/depression.
There are three possible explanations for these
ﬁndings. In chronic patient populations disease
severity is a covariate that might count for the unex-
pected correlation between age and self-care limita-
tions. Because there was no disease severity index
available in this study, this is a hypothesis that
should be tested in future research. The unusual
pattern in usual activities may be due to the fact that
younger patients may suffer from their disease less
long than the older patients. Therefore, they may
not have adapted certain coping strategies, such as
changing lifestyle, habits, and ways to perform
usual activities to the same extent as the older
patients. Because older patients have adopted their
usual activities to their current physical capacity,
they might no longer feel equally impaired in per-
forming usual activities. The same applies for the
self-care dimension. The longer people suffer from a
chronic disease, the more they ﬁnd ways to get
around this problem. The unusual pattern observed
on the pain/discomfort dimension may be explained
by the fact that older patients generally have less
comorbidities at transplantation than younger
patients and thus a better self-reported health status
afterward. There is evidence that older patients with
many comorbidities are less likely to be trans-
planted than younger patients [57]. Patients with
much comorbidity, e.g., those with cardiovascular
diseases who were not transplanted at a younger
age, tend to grow old on dialysis and were hence not
included in our study of transplant patients.
The second hypothesis (H2) could not be rejected
because women did show higher levels of anxiety/
depression than men, analogous to ﬁndings from
the general public in different countries [2,53–
56,58–61].
For the discriminant validity test, percentages of
patients reporting problems on the respective EQ-
5D dimensions were compared to percentages of
people in the general public reporting problems on
the same dimensions. Renal transplant patients
scored worse on all EQ-5D dimensions than the
general Flemish public (H3), though not signiﬁ-
cantly on the self-care dimension. The latter obser-
vation may be due to the relatively restricted
formulation of the self-care question in the EQ-5D
(“I have no/some/severe problems with washing or
dressing myself”), whereas the other dimensions are
formulated in more general terms. The difference
persisted after correction for difference in age, sex,
and educational level, three aspects that differed sig-
niﬁcantly between both samples.
For almost all dimensions of the EQ-5D, the SF-
36 scores for all SF-36 domains differ signiﬁcantly
among patients grouped by their response on the
respective EQ-5D dimensions (H4). Differences in
SF-36 scores between comparable dimensions of the
EQ-5D and the SF-36 were larger than between
noncomparable dimensions, pointing at good con-
current validity of the EQ-5D. The response cate-
gories of the EQ-5D are very limited in comparison
to the response categories of the SF-36. This is an
acknowledged problem, however, for which the
proposed solution is to use a separate disease-spe-
ciﬁc instrument alongside the generic EQ-5D [3] if
more information about subdomains of health is
required. For use in economic evaluations, however,
the observed concurrent validity of the EQ-5D is
satisfactory, especially in view of the highly signiﬁ-
cant positive correlation between the EQ-5D index
score and the SF-36 score for general health
perception.
The classiﬁcation into depressed and not
depressed patients according to the EQ-5D was
highly comparable with the classiﬁcation of the BDI
(H5).  If  no  information  about  potential  reasons
for depressive symptomatology in renal transplant
patients is required, as in economic evaluations, the
use of the descriptive EQ-5D system may be
sufﬁcient.
A similar pattern was found for the MTSOSD
scale scores. Patients with more problems on self-
care, usual activities, pain/discomfort, and anxiety/
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depression have higher scores for symptom occur-
rence and symptom distress.
Conclusions
In conclusion, the results of this study show that the
EQ-5D has acceptable convergent and discriminant
validity and concurrent validity for the measure-
ment of health status in a renal transplant popula-
tion. The results of the EQ-5D in renal transplant
patients are in line with existing evidence. Conse-
quently, the use of the EQ-5D in the outcome meas-
urement of interventions for economic evaluations
will reveal results that are consistent with evidence,
which is an important indication for its validity in
renal transplant patients.
One of the merits of the EQ-5D is that it is a sim-
ple instrument that can easily be administered dur-
ing routine clinical practice. This feature makes the
instrument especially attractive from a research per-
spective. Given the relatively good indications of
validity of the instrument in a renal transplant pop-
ulation, we recommend further use of this instru-
ment in this patient group.
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grant from Fujisawa GmbH, Germany, and by a grant
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